Idexx Laboratories: A New Opportunity in Pet Health Investment
Idexx Laboratories presents a compelling long-term investment opportunity in the pet health sector, marked by consistent historical returns, innovative products like the InVue DX instrument, and stable recurring revenue streams. The company anticipates strong future growth in sales, EPS, and recurring revenue, despite recent analyst adjustments to price targets. Idexx maintains a "Moderate Buy" consensus from Wall Street analysts, reflecting its solid financial performance and potential for continued expansion in its diverse market segments.
10 Best Pet Stocks to Buy According to Hedge Funds
Central Garden & Pet Company (NASDAQ: CENT) is highlighted as one of the best pet stocks due to recent corporate developments. The company recently increased its stock repurchase program by an additional $100 million, appointed Kay M. Schwichtenberg to its Board of Directors, and released its fiscal Q1 2026 financial results showing $617 million in net sales. The company believes its stock is currently undervalued and expanded its gross margin by 110 basis points.
Are Wall Street Analysts Bullish on IDEXX Laboratories Stock?
IDEXX Laboratories (IDXX) has outperformed the broader market over the past year with a 39.9% surge, though it has faced a 6.8% YTD decline following a Q4 earnings report that missed gross margin expectations. Despite recent volatility, Wall Street maintaining a "Moderate Buy" consensus with a mean price target suggesting over 22% potential upside.
HighTower Advisors LLC Cuts Stock Position in IDEXX Laboratories, Inc. $IDXX
HighTower Advisors LLC has reduced its stake in IDEXX Laboratories by 13.3% in Q3, selling 4,259 shares but still holding 27,719 shares valued at $17.71 million. This comes as company insiders also sold 18,180 shares worth approximately $11.63 million, significantly decreasing their individual holdings. Despite these sales, institutional ownership remains high at 87.84%, with other major institutions increasing their positions, and analysts rating the stock a "Moderate Buy" with an average target price of $783.33.
IDEXX Laboratories, Inc. $IDXX Shares Sold by Factory Mutual Insurance Co.
Factory Mutual Insurance Co. reduced its stake in IDEXX Laboratories (NASDAQ:IDXX) by 25.0% in the third quarter, selling 15,300 shares and owning 45,800 shares worth $29.26 million. Despite this, other hedge funds increased their positions in IDXX. The company's stock has an average "Moderate Buy" rating from analysts with a consensus target price of $783.33.
Here’s Why IDEXX Laboratories (IDXX) Shares are Re-Rating to Historical Average
Conestoga Capital Advisors highlighted IDEXX Laboratories (IDXX) in its Q4 2025 investor letter, noting its industry leadership in diagnostic instruments and consumables for veterinary, food, and water testing. Despite weak veterinary traffic, IDXX continued to show strong organic revenue growth and earnings beats, leading its shares to re-rate back to historical valuation averages. The company had 55 hedge fund portfolios holding its stock at the end of Q3 2025.
Idexx Labs director Vandebroek sells $920k in shares
IDEXX Laboratories director Sophie V. Vandebroek sold 1,464 shares of common stock for approximately $920,293 and exercised options to acquire 945 shares. These transactions occurred on February 17, 2026. The insider sale comes as InvestingPro analysis suggests the stock is currently overvalued, despite the company reporting stronger-than-expected Q4 revenue but a slight miss on EPS.
Idexx Labs director Vandebroek sells $920k in shares
IDEXX Laboratories director Sophie V. Vandebroek sold 1,464 shares of the company's common stock for approximately $920,293 and simultaneously exercised options to acquire 945 shares. These transactions leave Vandebroek with 1,167 directly owned shares and 8,173 indirectly owned shares through a trust. The article also notes recent financial performance for IDEXX, including strong Q4 revenue growth that beat expectations, although Q4 EPS slightly missed forecasts in one report, and a recent price target reduction from BTIG due to concerns about 2026 guidance.
IDEXX Laboratories (NASDAQ:IDXX) EVP Sells $3,369,657.98 in Stock
IDEXX Laboratories' (NASDAQ:IDXX) EVP Michael Erickson sold 5,371 shares of company stock for over $3.36 million, reducing his ownership by nearly 30%. This sale follows the company reporting slightly missed EPS but increased revenue, and providing full-year 2026 guidance. IDEXX currently holds a "Moderate Buy" analyst consensus with a target price of $783.33.
Sophie Vandebroek Sells 1,464 Shares of IDEXX Laboratories (NASDAQ:IDXX) Stock
Sophie Vandebroek, a director at IDEXX Laboratories (NASDAQ:IDXX), sold 1,464 shares for approximately $920,300, reducing her stake by 69.32%. This sale occurred on February 17th at an average price of $628.62 per share. The company recently reported quarterly EPS of $2.92, slightly missing consensus, with revenue of $1.09 billion and provided FY2026 EPS guidance between $14.29 and $14.80.
Archer Daniels Midland Is Up 18% Year to Date. Here’s What to Expect in 2026
Archer Daniels Midland (ADM) stock has risen 18% year-to-date, trading near $68 per share, driven by improved earnings visibility and expectations of a cyclical trough in 2025. The company reported strong Q4 results and issued 2026 adjusted EPS guidance above 2025 levels, signaling a return to growth. Despite this, a valuation model suggests ADM is slightly overvalued at current levels, with future upside dependent on sustained improvement in crush margins and biofuel-driven demand.
DaVita Stock Is Up 35% Since February. Here’s Where Shares Could Go in 2026
DaVita (DVA) stock surged 35% in February 2026, driven by a strong Q4 2025 earnings beat, robust 2026 guidance forecasting a 33% EPS jump, and a strategic investment in Elara Caring to expand home kidney care. Analysts have raised price targets, recognizing DaVita's transition into a multi-vertical kidney care platform with significant upside potential, despite some near-term risks and Wall Street's cautious stance. TIKR's valuation model projects a mid-case target price of $217.26 by December 2030, suggesting a 47% total return.
IDEXX Stock Has Rallied 40% Over the Past Year: Can a New CEO Keep the Momentum Going?
IDEXX Laboratories recently announced Michael Erickson will succeed Jay Mazelsky as CEO, following a year where shares surged significantly. Despite beating Q4 revenue estimates, concerns arose from a guided 2% decline in U.S. same-store clinical visits, causing a slight stock dip. Analysts project a potential 38% upside to $873 by December 2028, contingent on sustained 9% revenue growth and 33% operating margins, though the exit multiple already aligns with current market pricing.
JPMorgan Chase & Co. Buys 326,348 Shares of IDEXX Laboratories, Inc. $IDXX
JPMorgan Chase & Co. significantly increased its stake in IDEXX Laboratories, purchasing 326,348 additional shares to own 869,930 shares, valued at roughly $555.8 million. This acquisition makes their total holding approximately 1.09% of the company. Despite missing EPS estimates by a narrow margin, IDEXX Laboratories reported strong revenue growth and analysts maintain a "Moderate Buy" rating with an average target price of $783.33.
Marble Harbor Investment Counsel LLC Reduces Holdings in IDEXX Laboratories, Inc. $IDXX
Marble Harbor Investment Counsel LLC reduced its stake in IDEXX Laboratories by 5.8% in Q3, now holding 36,655 shares worth $23.42 million. This reduction comes amid varied analyst ratings, including price target increases and decreases, and an insider stock sale by EVP George Fennell totaling over $7.3 million. IDEXX recently reported a slight EPS miss but strong revenue growth and provided a positive FY2026 EPS guidance.
NEOS Investment Management LLC Grows Holdings in IDEXX Laboratories, Inc. $IDXX
NEOS Investment Management LLC significantly increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 82.7% in Q3, now owning 30,051 shares valued at $19.2 million. This comes as an EVP sold a portion of his holdings, while institutional investors collectively own 87.84% of the stock. Despite a slight EPS miss, the company beat revenue estimates, provided positive FY2026 guidance, and holds a "Moderate Buy" consensus rating with a $783.33 price target.
Glenview Trust Co Increases Stake in IDEXX Laboratories, Inc. $IDXX
Glenview Trust Co increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.0% in the third quarter, owning 40,729 shares valued at $26.02 million. This move is part of a broader trend of institutional investors modifying their holdings in IDXX. Despite a recent insider stock sale and some analyst target price reductions, the stock currently holds a "Moderate Buy" consensus rating among analysts.
IDEXX Laboratories, Inc. $IDXX is TimesSquare Capital Management LLC's 6th Largest Position
TimesSquare Capital Management LLC has reduced its stake in IDEXX Laboratories (NASDAQ:IDXX) by 4.1%, but it remains their 6th largest holding, representing 1.8% of their investment portfolio. Other institutional investors have also adjusted their positions in the company. An IDEXX executive recently sold over $7.3 million worth of shares, reducing their ownership by 53.60%. The company reported a slight EPS miss but exceeded revenue expectations for its latest quarter and analysts have a "Moderate Buy" rating with a consensus price target of $783.33.
IDEXX Laboratories Inc. (IDXX) Shows Resilience as Analysts Reassess Targets
IDEXX Laboratories Inc. (NASDAQ: IDXX) reported strong Q4 2025 earnings with revenue up 14% to $1.09 billion and EPS up 18% to $3.08, exceeding analyst expectations. Despite BTIG lowering its price target to $800 due to concerns over 2026 guidance, the firm maintained a Buy rating, acknowledging IDEXX's profitability and growth in its companion animal business. The company forecasts 2026 revenue of $4.63–$4.72 billion and EPS of $14.29–$14.80, actively addressing potential headwinds such as fewer pet visits with strategic initiatives.
IDEXX Laboratories Inc. (IDXX) Shows Resilience as Analysts Reassess Targets
IDEXX Laboratories Inc. (IDXX) demonstrated resilience with strong Q4 2025 earnings, exceeding revenue and EPS expectations. Despite a lowered price target from BTIG due to concerns about 2026 guidance, the company maintains high profitability and growth in its companion animal business. Headwinds include fewer pet visits impacting operating margins, which IDEXX plans to offset with new InVueDx system placements and price growth.
IDEXX Laboratories Inc. (IDXX) Shows Resilience as Analysts Reassess Targets
IDEXX Laboratories Inc. (IDXX) is demonstrating resilience despite a recent price target reduction by BTIG, which cited concerns over 2026 guidance. The company reported strong Q4 2025 earnings, exceeding analyst expectations with significant revenue and EPS growth, particularly in its companion animal segment. While facing headwinds from fewer pet visits, IDEXX plans to offset this with strategic placements of new systems and anticipates continued revenue growth.
IDEXX Laboratories Inc. (IDXX) Shows Resilience as Analysts Reassess Targets
IDEXX Laboratories Inc. (IDXX) demonstrated strong Q4 2025 earnings with revenue up 14% and EPS up 18%, exceeding analyst expectations, driven by its companion animal business. Despite this, BTIG lowered its price target due to concerns over the company's 2026 guidance, which anticipates a slight drag from fewer pet visits but expects growth from pricing and new system placements. IDEXX, a highly profitable medical technology company, continues to focus on long-term revenue growth and shareholder value.
IDEXX Laboratories Inc. (IDXX) Shows Resilience as Analysts Reassess Targets
IDEXX Laboratories Inc. (IDXX) demonstrated resilience with strong Q4 2025 earnings, surpassing revenue and EPS expectations, despite a lowered price target from BTIG due to concerns about 2026 guidance. The company’s core companion animal business showed significant growth, driven by instrument sales, and it continues to expect solid revenue and EPS for 2026, mitigating headwinds like fewer pet visits with strategic initiatives.
10 Best Medical Technology Stocks to Invest In
This article identifies IDEXX Laboratories Inc. (NASDAQ: IDXX) as a top medical technology stock to consider for investment, highlighting its strong Q4 2025 earnings and robust performance. Despite a recent price target reduction by BTIG due to 2026 guidance concerns, IDEXX demonstrated significant revenue and EPS growth, particularly in its companion animal business. The company continues to project solid revenue and EPS for 2026, driven by strategic placements of its diagnostic systems and global price growth.
Assetmark Inc. Has $32.74 Million Position in IDEXX Laboratories, Inc. $IDXX
Assetmark Inc. reduced its stake in IDEXX Laboratories by 20.9% in Q3, selling 13,534 shares and now holding 51,251 shares valued at $32.74 million. Additionally, IDEXX EVP George Fennell sold 11,345 shares on February 10th for approximately $7.34 million, reducing his ownership by over 50%. Despite missing Q4 EPS targets by $0.01, IDEXX saw a 14.3% revenue jump to $1.09 billion and has an average analyst target price of $783.33 with mostly buy ratings.
IDEXX Laboratories (IDXX) Announces Board Changes Ahead of 2026 Annual Meeting
IDEXX Laboratories (IDXX) has announced upcoming changes to its Board of Directors ahead of its 2026 Annual Meeting. Ms. M. Anne Szostak will retire from the Board effective May 12, 2026, after serving since 2012. Concurrently, Michael G. Erickson, PhD, will join as a Class II member, maintaining the overall size of the Board.
Wealthfront Advisers LLC Buys 2,463 Shares of IDEXX Laboratories, Inc. $IDXX
Wealthfront Advisers LLC increased its stake in IDEXX Laboratories by 35.1%, purchasing 2,463 additional shares to own a total of 9,477 shares valued at $6.055 million. This comes as EVP George Fennell sold a significant portion of his holdings (11,345 shares), reducing his ownership by over 50%. The company recently beat quarterly earnings estimates and provided strong FY2026 guidance, yet analyst opinions are varied, with a "Moderate Buy" consensus and an average price target of $783.33.
Is Waters a Better Buy Than Thermo Fisher Scientific?
This article analyzes whether Waters (WAT) is a better investment than Thermo Fisher Scientific (TMO). It suggests that WAT offers superior revenue growth, better profitability, and a relatively lower valuation compared to TMO, despite TMO's recent stock decline. The comparison is supported by side-by-side financial metrics and historical market performance data for both companies.
IDEXX Laboratories to Present at Two Institutional Investor Conferences
IDEXX Laboratories, Inc. (NASDAQ: IDXX) announced its participation in two upcoming institutional investor conferences. Mike Lane and Andrew Emerson will represent IDEXX at the virtual BofA Securities Animal Health Summit on February 26, while CEO Jay Mazelsky will present at the 47th Annual Raymond James Institutional Investors Conference on March 2. Live webcasts and archived versions of both presentations will be available on the IDEXX investor relations website.
Artivion (NYSE:AORT) Misses Q4 CY2025 Sales Expectations
Artivion (NYSE:AORT) reported Q4 CY2025 revenue of $116 million, missing analyst estimates but showing a 19.2% year-on-year increase. The company's full-year revenue guidance exceeded expectations, and its non-GAAP EPS was in line with consensus. Despite the revenue miss and a slight dip in stock price post-announcement, Artivion showcased strong adjusted constant currency revenue growth for the full year 2025 and improved operating margins.
IDEXX Laboratories to Present at Two Institutional Investor Conferences
IDEXX Laboratories, Inc. (NASDAQ: IDXX) announced its participation in two upcoming institutional investor conferences. Mike Lane and Andrew Emerson will speak at the virtual BofA Securities Animal Health Summit on February 26, and Jay Mazelsky will present at the 47th Annual Raymond James Institutional Investors Conference on March 2. Live webcasts and archived editions of these presentations will be available on the IDEXX investor relations website.
IDEXX Laboratories to Present at Two Institutional Investor Conferences
IDEXX Laboratories, Inc. (NASDAQ: IDXX) will participate in two upcoming institutional investor conferences. Mike Lane and Andrew Emerson will present at the virtual BofA Securities Animal Health Summit on February 26, 2026, and Jay Mazelsky will present at the 47th Annual Raymond James Institutional Investors Conference on March 2, 2026. Webcasts of these presentations will be available on the IDEXX investor relations website.
4,049 Shares in IDEXX Laboratories, Inc. $IDXX Purchased by Krilogy Financial LLC
Krilogy Financial LLC has acquired 4,049 shares of IDEXX Laboratories, Inc. (IDXX), valued at approximately $2.587 million, as reported in their recent 13F filing. Other institutional investors have also adjusted their holdings in the veterinary diagnostic company. IDEXX Laboratories recently reported strong quarterly earnings, beating analyst estimates, and several Wall Street analysts have issued "Buy" ratings and upward-revised price targets for the stock.
Rhumbline Advisers Reduces Position in IDEXX Laboratories, Inc. $IDXX
Rhumbline Advisers decreased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.1% during the third quarter, selling 5,492 shares and now owning 174,026 shares valued at $111.18 million. Despite this reduction, other institutional investors like Geode Capital Management and Bank of New York Mellon Corp increased their positions significantly. The company recently reported strong quarterly earnings, topping analyst estimates, and has a "Moderate Buy" consensus rating from analysts with an average target price of $783.33.
Caprock Group LLC Invests $5 Million in IDEXX Laboratories, Inc. $IDXX
Caprock Group LLC recently invested approximately $5 million in IDEXX Laboratories, Inc. by acquiring 7,721 shares, making institutional investors collectively own about 87.84% of the company. IDEXX Laboratories exceeded Q3 earnings expectations with an EPS of $3.08 and revenue of $1.09 billion, while analysts maintain a "Moderate Buy" rating with an average price target of $783.33. The company has also provided positive FY2026 EPS guidance, and its stock shows both recent insider selling and strong financial metrics.
IDEXX Laboratories Inc(IDXX.US) Officer Sells US$7.34 Million in Common Stock
An officer at IDEXX Laboratories Inc (IDXX.US), FENNELL GEORGE, sold 11,345 shares of common stock on February 10, 2026. The transaction was valued at approximately $7.34 million, with an average selling price of $646.716 per share. This sale is part of the required disclosure for insiders under federal securities laws.
Insider Selling: IDEXX Laboratories (NASDAQ:IDXX) EVP Sells 11,345 Shares of Stock
IDEXX Laboratories (NASDAQ:IDXX) Executive Vice President George Fennell sold 11,345 shares of the company's stock on February 10th for over $7.3 million, reducing his ownership by 53.6%. This insider selling follows strong quarterly earnings that beat expectations, with the company reporting $3.08 EPS and $1.09 billion in revenue, and issuing positive FY 2026 EPS guidance. Analysts currently maintain a "Moderate Buy" rating for IDEXX, with an average target price of $783.33.
Midwest Trust Co Purchases 12,179 Shares of IDEXX Laboratories, Inc. $IDXX
Midwest Trust Co significantly increased its stake in IDEXX Laboratories (NASDAQ:IDXX) by 760.2% in Q3, purchasing 12,179 additional shares, bringing its total holdings to 13,781 shares valued at $8.81 million. This increase follows IDEXX beating Q4 earnings expectations with $3.08 EPS and $1.09 billion revenue, and their FY 2026 guidance projects EPS between $14.29 and $14.80. The company currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $783.33.
Baron Partners Fund is Leveraging IDEXX Laboratories’ (IDXX) Long-Term Growth Drivers
Baron Partners Fund highlights IDEXX Laboratories (IDXX) as a key holding for its long-term growth potential, attributing its success to new product innovations and accelerated secular trends in pet ownership and care spending. The fund, which significantly outperformed its benchmarks in Q4 2025 and the full calendar year, believes IDEXX's competitive trends are outstanding and expects continued contributions from proprietary innovations like InVue, MultiCue, and CancerDX. Despite a recent monthly dip, IDEXX's shares are up over 41% in the past year, reflecting its strong market capitalization and growth prospects.
What To Expect From Artivion's (AORT) Q4 Earnings
Artivion (AORT) is set to report its Q4 earnings this Thursday. Analysts project a 20.2% year-on-year revenue growth to $117 million and adjusted earnings of $0.18 per share. The company has a history of exceeding revenue estimates, and recent peer performance in the healthcare equipment sector offers mixed signals.
Inogen (INGN) Loses 10.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Inogen (INGN) has seen a 10% decline in stock value over the past four weeks, reaching an oversold position according to its Relative Strength Index (RSI) of 29.69. This technical indicator, combined with rising earnings estimates from Wall Street analysts and a Zacks Rank #2 (Buy), suggests a potential trend reversal and rebound for the stock. Investors may find this an opportune time to consider entry.
Companion Animal Healthcare Market Is Going to Boom | Major
A new study by HTF MI Research evaluates the global Companion Animal Healthcare Market, projecting its size, trends, and forecast to 2033. The market, driven by rising pet ownership and humanization, includes pharmaceuticals, diagnostics, vaccines, and preventive care. Key players like Zoetis, Elanco, and Merck Animal Health are covered, with North America dominating and Asia-Pacific emerging as the fastest-growing region.
Candriam S.C.A. Has $14.68 Million Position in IDEXX Laboratories, Inc. $IDXX
Candriam S.C.A. significantly reduced its stake in IDEXX Laboratories (NASDAQ:IDXX) by 70.9% in the third quarter, selling 56,053 shares and retaining 22,975 shares valued at approximately $14.68 million. Despite this reduction, IDEXX Laboratories reported strong quarterly earnings, beating expectations with $3.08 EPS and $1.09 billion in revenue, and provided optimistic FY2026 guidance. The stock holds a "Moderate Buy" consensus rating from analysts, with mixed price targets reflecting varying expert opinions.
Inspire Medical Systems (INSP) Q4 Results: Anticipated Outcomes
Inspire Medical Systems (INSP) is set to announce its Q4 financial results, with analysts projecting $266.3 million in revenue and $0.68 adjusted EPS. The company has a history of outperforming revenue expectations but has seen a significant stock decline recently amid broader market volatility. The article provides context by reviewing the performance of industry peers and discusses the current economic climate affecting the healthcare equipment sector.
Piper Sandler Maintains IDEXX Laboratories Inc(IDXX.US) With Hold Rating, Cuts Target Price to $750
Piper Sandler analyst David Westenberg has reiterated a hold rating on IDEXX Laboratories Inc (IDXX.US) while lowering the target price from $775 to $750. According to TipRanks data, Westenberg has a 50.2% success rate and an average return of 11.0% over the past year. TipRanks provides analysis data from third-party financial analysts, calculating success rates and average returns based on virtual portfolio performance.
Oppenheimer Asset Management Inc. Sells 3,458 Shares of IDEXX Laboratories, Inc. $IDXX
Oppenheimer Asset Management Inc. reduced its stake in IDEXX Laboratories by 10.3%, selling 3,458 shares and now holding 30,170 shares valued at $19.28 million. Meanwhile, several other institutional investors like Geode Capital Management and Bank of New York Mellon Corp significantly increased their positions in the company. IDEXX Laboratories recently exceeded Q4 earnings and revenue estimates and maintains a "Moderate Buy" consensus rating from analysts.
CF Industries Holdings Inc. (NYSE:CF) Shows Strong Technical Setup for Potential Breakout
CF Industries Holdings Inc. (NYSE:CF) is exhibiting a strong technical setup, indicating a potential price breakout. The company boasts a high ChartMill Technical Rating of 8 out of 10, reflecting a sustained uptrend and agreement across various time periods, with its price above all key moving averages. Additionally, its Setup Quality Rating of 8 suggests it's in a favorable consolidation phase, offering a defined entry point for traders ahead of a possible upward movement.
Is Nuveen ESG Mid-Cap Growth ETF (NUMG) a Strong ETF Right Now?
This article evaluates the Nuveen ESG Mid-Cap Growth ETF (NUMG), a smart beta ETF launched in 2016, highlighting its structure, expense ratio, and sector allocations. It notes the ETF's underperformance year-to-date and over the last 12 months, before concluding with a mention of alternative ESG ETFs for investors to consider.
Envestnet Asset Management Inc. Trims Stock Position in IDEXX Laboratories, Inc. $IDXX
Envestnet Asset Management Inc. recently decreased its stake in IDEXX Laboratories (NASDAQ:IDXX) by 12.6%, selling 28,990 shares to hold a total of 201,921 shares valued at approximately $129 million. Despite this trim, Wall Street analysts maintain a "Moderate Buy" rating for IDEXX, with an average target price of $777.78, reflecting a generally positive outlook. The company also reported strong quarterly earnings, beating consensus estimates and providing optimistic FY2026 guidance, though its current P/E ratio indicates a rich valuation.
Neogen Recall Puts Veterinary Quality Controls And Investor Confidence In Focus
Neogen Corporation initiated a voluntary recall of its HYCOAT Hyaluronate Sodium Sterile Solution due to microbial contamination, affecting its standing in the veterinary market. This recall places scrutiny on Neogen's quality controls, supplier oversight, and its Animal Safety segment's profitability struggles. Investors are watching how the company navigates regulatory relationships, restores trust, and manages financial impacts in a competitive landscape with rivals like Zoetis and IDEXX.
